ABSTRACTS – ORAL PRESENTATIONS - AMCA, spol. s r.o.

European Myeloma Network (EMN) was working on standardization of this analytical
method and its implementation into routine clinical examination of MG cases (Rawstron
et al., 2008). Thus a uniform protocol for the analysis of plasma cell dyscrasias (PCD)
developed by EuroFlow consortium is widely recommended for MG analyses, especially
in clinical studies (van Dongen et al., 2012).
Aim: Analysis of different MG cases using Euroflow settings and validation/verification of
this method for routine analyses.
Subjects and methods: There were analysed 104 newly diagnosed MGs included 62
multiple myeloma (MM) patients and 42 subjects with monoclonal gammopathy of
undetermined significance (MGUS). Two 8-colours PCD tubes were prepared according
to EuroFlow standard operation procedure (SOP) and analysed on flow cytometer used
EuroFlow settings. Acquired data were reanalysed by Infinicyt software and compare
with common analyses done in laboratory.
Results: Using EuroFlow approach for MG analyses did not show any significant
difference when compared to common plasma cell (PC) analyses. PCs were detectable,
although CD138-Pacific Orange and lambda-APCH7 were not very bright in some cases.
Merging of standardized data from two 8-colours PCD tubes increased number of
analysed PCs what could overcome problem with low PC percentage, but a problem with
clonality assessment remains. When other MGs than MM are analysed (MGUS with low
PC infiltration, primary amyloidosis, lymphoplasmocytic lymphoma etc.) and different
PC/plasmablast/B cell subpopulations should be detected, common analysis provides
better identification of clonal cells. On the other hand, EuroFlow approach brings more
information than common analysis and allows detection of specific PC phenotype. The
important disadvantage of this approach is the price of some monoclonal antibodies and
also specific software which is relatively high and thus unavailable for small laboratories.
Conclusion: Analyses of MGs using EuroFlow settings are useful especially for
reference laboratories participating in clinical studies as this approach allows sharing of
standardized data for further analyses.
Acknowledgements
This work was supported by MSM0021622434, IGA NT12425 and GACR P304/10/1395
grants.
References
1. Paiva, B., Almeida, J., Pérez-Andrés, M. et al.: Utility of flow cytometry
immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders.
- Cytometry B Clin Cytom 78(4): 239-252, 2010.
2. Rawstron, A.C., Orfao, A., Beksac, M. et al.: Report of the European Myeloma
Network on multiparametric flow cytometry in multiple myeloma and related disorders.
- Haematologica 93(3):431-438, 2008.
3. van Dongen, J.J., Lhermitte, L., Böttcher, S. et al.: EuroFlow antibody panels for
standardized n-dimensional flow cytometric immunophenotyping of normal, reactive
and malignant leukocytes. - Leukemia 26(9):1908-1975, 2012.
Analytical Cytometry VII 165